(VIANEWS) – EQUASENS (EQS.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| EQUASENS (EQS.PA) | €57.90 | 1.88% | 27.25% |
| SARTORIUS STED BIO (DIM.PA) | €232.60 | 0.6% | 18.66% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. EQUASENS (EQS.PA)
1.88% Forward Dividend Yield and 27.25% Return On Equity
Equasens Société anonyme provides healthcare IT solutions in Europe. It offers id. PATIENT, a business software; id. MOBILITY, a back-office management software; pandaLAB Pro, an instant messaging solution; Id. VENTE, an HAS-certified drug database; Id. COMMANDE, an order management module; dispensing robots; Services Ségur id; id. DOSAGE, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; Visiodroits module; and Website connector. The company also provides id. DESK, an informative and interactive dashboard; id. UP!, a real-time monitoring and control application of id management software; id. EASYQ, a queue management solution; Miaterapia; Id. SHOW, an application for managing real-time communications on pharmacy screens; Pharmaweb; TsGatePro; LMO, a dispensary business software; and LGO, a dispensary management software. In addition, it offers DOMILINK HAD software; mobiSOINS mobility tool; MEMORialis, support software for alzheimer's monitoring teams; HOSPILINK, an hospital information system applications; HOSPILINK DPI, a computerized patient file; HOSPILINK LOOKUP Big Data; eNephro solutions; NOVIAcare solutions; KAP&LINK2, a contact chip card reader terminal and NFC reader; eS-KAP-Ad, a connected nomadic tool incorporating software; KAP-INSIDE, a mobile terminal; and TI-KAP allowing access to contact and contactless cards. Further, the company provides AUTHENTICATOR, a patented authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; ExpressVitale; MédiStory, that automates the transfer of invoicing to the healthcare professional's accounting. Additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 18.98. Meaning, the purchaser of the share is investing €18.98 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.25%.
Sales Growth
EQUASENS’s sales growth for the current quarter is negative 2.1%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 223.12M for the twelve trailing months.
Volatility
EQUASENS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.06%, a negative 0.03%, and a positive 2.04%.
EQUASENS’s highest amplitude of average volatility was 1.52% (last week), 1.47% (last month), and 2.04% (last quarter).
More news about EQUASENS.
2. SARTORIUS STED BIO (DIM.PA)
0.6% Forward Dividend Yield and 18.66% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €4.9.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 47.47. Meaning, the purchaser of the share is investing €47.47 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.66%.
Volatility
SARTORIUS STED BIO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.09%, a positive 1.10%, and a positive 2.35%.
SARTORIUS STED BIO’s highest amplitude of average volatility was 2.73% (last week), 1.89% (last month), and 2.35% (last quarter).
Volume
Today’s last reported volume for SARTORIUS STED BIO is 16172 which is 79.49% below its average volume of 78884.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Mar 30, 2023, the estimated forward annual dividend rate is 1.44 and the estimated forward annual dividend yield is 0.6%.
Sales Growth
SARTORIUS STED BIO’s sales growth for the current quarter is negative 4.1%.
More news about SARTORIUS STED BIO.
